Document text
Principal Investigator: David S Perlin
Organization: HACKENSACK UNIVERSITY MEDICAL CENTER
Fiscal Year: 2022
Award: $7,558,755
Funding agency: National Institute of Allergy and Infectious Diseases
The MAVDA Administrative Core (MAC) will be established as an integrated, priority-setting consortium
involving the Program Directors (PDs), a Business Director (BD), an internal MAVDA Leadership Team (MLT),
and a Scientific Advisory Board (SAB) with programmatic involvement from NIAID to enhance potential product
outcome in the form of antivirals against SAR-CoV-2 and other viruses with pandemic potential. The
management function is designed to provide administrative support that facilitates the success of individual
projects, promotes effective integration and allocation of support functions and resources, and stimulates
scientific exchange between MAVDA members, thus ensuring that the overall program achieves its objectives.
The MAC will be overseen by co-PDs, Dr. David S. Perlin and Dr. Charles M. Rice, who will be supported by an
experienced BD and appropriate support staff to coordinate and manage all administrative functions. To best
advance MAVDA's objectives, the MAC will coordinate regular meetings of Project Leaders, Pharma/Biotech
Partners, Core Directors, and SAB members. The meetings are designed to advance compounds through the
discovery matrix enabling timely and objective ‘Go/No Go’ decision making. A secure web-based platform will
be used to foster interactions between Projects and Cores. The MAC will facilitate an annual review meeting with
the SAB, and a reverse site visit at NIAID. It will produce and submit the annual progress report to the NIH, and
it will coordinate research publications, meeting presentations, reports and press releases. MAVDA is designed
to encourage partnering among academia and industry, specifically Pharma and Biotech companies, and has
protections in place to protect the intellectual property of participating organizations. There is universal
confidentiality between projects and cores, with data shared as required to advance compounds and at no risk
to the project team. As MAVDA retains no IP rights, all IP rights reside in the host institutions or per agreements
with industry partners. The MAC will execute the following Specific Aims: 1) establish a highly efficient
management structure that supplies essential oversight and guidance for Project Leaders and Core Directors,
effectively integrates the Scientific Advisory Board as strategic advisors in the discovery process, and promotes
scientific exchange; 2) maximize allocation of resources and prioritize compound development by establishing
critical metrics for ‘Go/No Go’ decision making and resource allocations by supporting close interactions of
Project Leaders and Core Directors and scheduling regular reviews; 3) annually assess project performance and
prepare interim and year-end reports; 4) solicit and manage Developmental and Mentored Research Projects;
5) coordinate publications, presentations of results, and press releases from these studies and develop a
managerial plan for conflict resolution and other operational issues; and 6) establish an internal organizational
structure that addresses logistics for material transfer agreements, intellectual property filings, licensing
opportunities, and negotiations.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Academia><Address><Agreement><Antiviral Agents><Antiviral Drugs><Antivirals><Biotech><Biotechnology><Businesses><COVID-19 virus><COVID19 virus><Ching Lo><CoV-2><CoV2><Decision Making><Development><Ensure><Fostering><Goals><Health><Health Care Systems><Healthcare Systems><Individual><Industry><Institution><Intellectual Property><Investigational Drugs><Investigational New Drugs><Jing Luo><Jingluo><Lead><Leadership><Licensing><Logistics><Mediation><Medicinal Chemistry><Medicine><Mentors><Meridians><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Negotiating><Negotiation><New Jersey><On-Line Systems><Online Systems><Organization Charts><Outcome><Output><Pb element><Performance><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacology><Press Releases><Process><Progress Reports><Publications><R-Series Research Projects><R01 Mechanism><R01 Program><Reporting><Research><Research Grants><Research Project Grants><Research Projects><Research Resources><Resource Allocation><Resources><Rice><Rights><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Schedule><Scientific Publication><Secure><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site Visit><Structure><Time><Travel><United States National Institutes of Health><Virus><Wuhan coronavirus><anti-viral agents><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral compound><antiviral development><antiviral drug development><antiviral medication><antiviral therapeutic><antiviral therapeutic development><antiviral therapy development><base><conflict resolution><coronavirus disease 2019 virus><coronavirus disease-19 virus><data sharing><design><designing><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><drug development><drug discovery><experience><hCoV19><heavy metal Pb><heavy metal lead><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><material transfer agreement><meetings><member><metropolitan><nCoV2><online computer><organizational structure><pandemic><pandemic disease><pre-clinical><pre-clinical development><preclinical><preclinical development><programs><success><virology><web based>